Cidara Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Cidara Therapeutics

19/03/2024 13:06

* Cidara Therapeutics Inc  CDTX.OQ   CDTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 21
(estimated) for the period ending December 31 2023
    * The San Diego California-based  company is expected to
report a
12.9% increase in revenue to $11.542 million from $10.22 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Cidara Therapeutics Inc
is for
a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $5.50​, above​ its last closing price
of $0.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.16       -0.16      -0.09     Beat    44.6
 Jun. 30 2023  -0.10       -0.13      -0.14     Missed  -7.7
 Mar. 31 2023  -0.02       -0.04      0.03      Beat    181.8​
 Dec. 31 2022  -0.21       -0.17      -0.19     Missed  -13.4
 ​​Sep.        0.19        0.18       0.17      Missed  -5.6
 30 2022                                                
 Jun. 30 2022  -0.28       -0.28      -0.19     Beat    32.1​
 Mar. 31 2022  -0.28       -0.29      -0.27     Beat    8.2
 Dec. 31 2021  -0.32       -0.34      -0.26     Beat    24.5
 This summary was machine generated March 19 at 13:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)